Zacks Investment Research downgraded shares of Curis, Inc. (NASDAQ:CRIS) from a hold rating to a sell rating in a research report sent to investors on Friday.
According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “
A number of other research analysts have also recently commented on the company. Guggenheim initiated coverage on Curis in a research note on Monday, October 23rd. They issued a buy rating and a $7.00 target price on the stock. ValuEngine cut Curis from a hold rating to a sell rating in a research note on Friday, September 15th. Finally, BidaskClub cut Curis from a hold rating to a sell rating in a research note on Thursday, July 27th. Three equities research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. Curis presently has an average rating of Hold and a consensus price target of $6.50.
Curis (NASDAQ CRIS) opened at $1.03 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 5.15 and a quick ratio of 5.15. Curis has a 12 month low of $0.99 and a 12 month high of $3.72.
Curis (NASDAQ:CRIS) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02). The firm had revenue of $2.44 million during the quarter, compared to the consensus estimate of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. The firm’s revenue was up 38.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.21) EPS. sell-side analysts anticipate that Curis will post -0.41 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by BBNS and is the property of of BBNS. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/curis-inc-cris-downgraded-to-sell-at-zacks-investment-research/1774593.html.
Several large investors have recently made changes to their positions in the company. First Eagle Investment Management LLC grew its stake in shares of Curis by 10.4% during the third quarter. First Eagle Investment Management LLC now owns 26,508,672 shares of the biotechnology company’s stock valued at $39,498,000 after buying an additional 2,500,000 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Curis by 2.6% during the second quarter. Vanguard Group Inc. now owns 4,955,068 shares of the biotechnology company’s stock valued at $9,365,000 after buying an additional 127,443 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Curis by 62,201.8% during the third quarter. JPMorgan Chase & Co. now owns 2,381,798 shares of the biotechnology company’s stock valued at $3,691,000 after buying an additional 2,377,975 shares during the last quarter. State Street Corp grew its stake in shares of Curis by 10.4% during the second quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock valued at $3,511,000 after buying an additional 175,424 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Curis by 3.8% during the second quarter. Northern Trust Corp now owns 1,334,679 shares of the biotechnology company’s stock valued at $2,523,000 after buying an additional 49,310 shares during the last quarter. 46.01% of the stock is currently owned by hedge funds and other institutional investors.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with our FREE daily email newsletter.